International Cannabis Weekly: 464

MAJORITY OF UK MEDICAL CANNABIS FLOWER NOW AT 25% THC OR ABOVE, NEW DATA SHOWS

Earlier this month, we published new data from two separate Freedom of Information (FOI) requests providing the most complete and up-to-date picture yet of the UK’s medical cannabis market.

READ MORE  »

IS IT AN OPEN GOAL FOR GERMANY’S NEW CANNABIS MEDICINE

READ MORE »

DEA RELEASES FULL CANNABIS RESCHEDULING HEARING TRANSCRIPT

READ MORE »

• Barcelona launches Plan Druida crackdown against the majority of cannabis social clubs.
• Remexian Pharma is surging ahead one year on from its High Tide acquisition as revenues top $30m.
• New white paper is calling for NHS cannabis pilot and parliamentary industry inquiry.
• UK employers have the same duty of care to employees on medical cannabis as any other treatment says clinic.
• The European Union has set new THC limits for hemp-leaf tea from January 2027 onwards.
• Germany becomes Europe’s largest regulated cannabis market amid rapid medical growth.
• Czechia is considering brand new limits for alcohol, energy drinks and CBD products.
• Why did Germany’s BfArM revise cannabis import figures for Q1 2026 by nearly 20 tonnes?

LEARN MORE »

• Illinois adds sickle cell disease and chronic pain condition to medical cannabis programme.
• Missouri receives almost 900 applications for its final cannabis microbusiness licensing round.
• US researchers call for hemp rules that protect consumers without punishing farmers.
• Grown Rogue acquires PharmaCann assets to capitalise on New York’s indoor cultivation shortage.
• Black Cannabis Week returns to Philadelphia with expanded industry and community programming.
• SOL launches The Penthouse, aiming to reinvent the traditional cannabis retail experience.
• Cannabis cultivation begins at new Lexington facility serving Kentucky’s medical market.

• Canopy Growth prepares to bring its seed-to-patient cannabis model into Europe.
• Germany’s medical cannabis boom is reshaping global marijuana markets and trade flows.
• Canadian licensed producers expand their European cannabis presence as demand accelerates.
• Aurora Cannabis urges shareholders to reject Curaleaf’s hostile takeover proposal.
• Canadian cannabis market developments signal further changes across the international industry.
• Avant Brands has completed European Union Good Manufacturing Practice audit at its Flowr cultivation facility.
• TerrAscend shareholders approve key resolutions supporting potential US exchange listing plans.

• Flextem enters Brazil with pharmaceutical cannabis products and expanded medical ambitions.
• Brazil sees medical cannabis import authorisations rise by almost 29% in 2026.
• Argentine court orders health insurer OSDE to cover prescribed medical cannabis treatment.
• Rising demand for medical cannabis highlights continued market growth across Argentina.

• Vitura CEO has admitted performance has been sobering following $4.4 million loss.
• Zelira is facing potential Australian Securities Exchange removal after failing to pay its listing fee.
• Cannim saga takes another turn as company heads towards sale to mystery buyer. 

• South African hemp pioneers build a new industry despite significant regulatory and financial challenges.